The association between depressive symptoms and neurocognitive impairment in people with well-treated HIV in Switzerland

Abstract

Background: Depression may contribute to neurocognitive impairment (NCI) in people with HIV (PWH). Attributing NCI to depression rather than to HIV is complicated as depression may be both a causal factor and an effect of NCI. This study aimed to determine the association between depressive symptoms and NCI among PWH with well-controlled infection. Methods: The Neurocognitive Assessment in the Metabolic and Ageing Cohort study is an ongoing, prospective, longitudinal study of PWH aged ≥45 years old nested within the Swiss HIV Cohort Study. Neurocognitive Assessment in the Metabolic and Ageing Cohort study participants underwent neurocognitive assessment and grading of depressive symptoms using the Centre for Epidemiological Studies Depression Scale. Neurocognitive impairment categories were defined using Frascati criteria. Participants with NCI related to neurological or psychiatric confounders other than depression were excluded. The cross-sectional association between the Centre for Epidemiological Studies Depression score and neurocognitive impairment was examined taking Centre for Epidemiological Studies Depression score as a continuous variable and then as a binary variable using two score thresholds, 16 and 27. Results: Excluding 79 participants with confounding factors, 902 participants were studied: 81% were men; 96% had plasma viral loads <50 copies/ml; 35% had neurocognitive impairment; 28% had Centre for Epidemiological Studies Depression scores ≥16. Higher Centre for Epidemiological Studies Depression scores were associated with female sex (p = 0.0003), non-Caucasian origin (p = 0.011) and current/past intravenous drug use (p = 0.002). Whilst neurocognitive impairment was associated with higher Centre for Epidemiological Studies Depression scores, the Centre for Epidemiological Studies Depression score was a poor predictor of having neurocognitive impairment (area under the ROC curve 0.604). Applying a Centre for Epidemiological Studies Depression score threshold of 16 predicted the presence of neurocognitive impairment with a sensitivity of 38.3% (specificity 77.2%), increasing the threshold to 27 lowered sensitivity to 15.4% (specificity 93.6%). Conclusion: In this large cohort of PWH in Switzerland, we did not observe a Centre for Epidemiological Studies Depression score threshold that was sensitive in predicting neurocognitive impairment. As neurocognitive impairment was however associated with higher Centre for Epidemiological Studies Depression scores, the data support the screening for and treatment of depression among PWH diagnosed with neurocognitive impairment.

Keywords

HIV depression neurocognitive impairment neuropsychological testing ageing

Get full access to this article

View all access options for this article.

References

Heaton

Clifford

Franklin

Jr , et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 2010; 75(23): 2087–2096.

Simioni

Cavassini

Annoni

, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24(9): 1243–1250.

Metral

Darling

Locatelli

, et al. The neurocognitive assessment in the metabolic and aging cohort (NAMACO) study: baseline participant profile. HIV Med 2020; 21(1): 30–42.

European AIDS Clinical Society . Guidelines version 8.0 October 2015. Available at http://www.eacsociety.org/files/guidelines_8_0-english_web.pdf, 2015.

Nanni

Caruso

Mitchell

, et al. Depression in HIV infected patients: a review. Curr Psychiatry Rep 2015; 17(1): 530.

Fellows

Byrd

Morgello

, et al. Major depressive disorder, cognitive symptoms, and neuropsychological performance among ethnically diverse HIV+ men and women. J Int Neuropsychol Soc 2013; 19(2): 216–225.

Simoni

Safren

Manhart

, et al. Challenges in addressing depression in HIV research: assessment, cultural context, and methods. AIDS Behav 2011; 15(2): 376–388.

Jallow

Ljunggren

Wandell

, et al. HIV-infection and psychiatric illnesses - A double edged sword that threatens the vision of a contained epidemic: the greater stockholm HIV cohort study. J Infect 2017; 74(1): 22–28.

Choi

Boyle

Cairney

, et al. Prevalence, recurrence, and incidence of current depressive symptoms among people living with HIV in ontario, Canada: results from the ontario HIV treatment network cohort study. PLoS One 2016; 11(11): e0165816.

10.

Hammond

Crum

Treisman

, et al. Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. J Neurovirol 2016; 22(4): 479–487.

11.

Del Guerra

Fonseca

Figueiredo

, et al. Human immunodeficiency virus-associated depression: contributions of immuno-inflammatory, monoaminergic, neurodegenerative, and neurotrophic pathways. J Neurovirol 2013; 19(4): 314–327.

12.

Wright

Grund

Cysique

, et al. Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT strategic timing of antiretroviral treatment (START) trial. HIV Med 2015; 16(Suppl 1): 97–108.

13.

Castellon

Hardy

Hinkin

, et al. Components of depression in HIV-1 infection: their differential relationship to neurocognitive performance. J Clin Exp Neuropsychol 2006; 28(3): 420–437.

14.

McArthur

Brew

Nath

. Neurological complications of HIV infection. Lancet Neurol 2005; 4(9): 543–555.

15.

Metral

Nadin

Locatelli

, et al.

How helpful are the European AIDS clinical society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?

HIV Med 2019; 21(5): 342–348.

16.

Schulberg

Saul

McClelland

, et al. Assessing depression in primary medical and psychiatric practices. Arch Gen Psychiatry 1985; 42(12): 1164–1170.

17.

Mirza

Wolters

Swanson

, et al. 10 year trajectories of depressive symptoms and risk of dementia: a population-based study. Lancet Psychiatry 2016; 3(7): 628–635.

18.

Swiss HIV Cohort Study, Schoeni-Affolter

Ledergerber

, et al. Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol 2010; 39(5): 1179–1189.

19.

Lawton

Brody

. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9(3): 179–186.

20.

Chelune

Heaton

Lehman

RAW

. Neuropsychological and personality correlates of patients’ complaints of disability. In: Goldstein

Tarter

(ed) Advances in Clinical Neuropsychology. New York, NY: Plenum Press; 1986. 95–126.

21.

Gay

Kottorp

Lerdal

, et al. Psychometric limitations of the center for epidemiologic studies-depression scale for assessing depressive symptoms among adults with HIV/AIDS: a rasch analysis. Depress Res Treat 2016; 2016: 2824595.

22.

Marando

Gualberti

Costanzo

, et al. Discrepancies between physician’s perception of depression in HIV patients and self-reported CES-D-20 assessment: the DHIVA study. AIDS Care 2016; 28(2): 147–159.

23.

Antinori

Arendt

Becker

, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69(18): 1789–1799.

24.

Gazzard

Balkin

Hill

. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. AIDS Rev 2010; 12(2): 67–75.

25.

Schouten

Wit

, et al. Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy. AIDS 2016; 30(7): 1027–1038.

26.

Cysique

Deutsch

Atkinson

, et al. Incident major depression does not affect neuropsychological functioning in HIV-infected men. J Int Neuropsychol Soc 2007; 13(1): 1–11.

27.

Anagnostopoulos

Ledergerber

Jaccard

, et al. Frequency of and risk factors for depression among participants in the Swiss HIV cohort study (SHCS). PLoS One 2015; 10(10): e0140943.

28.

Robertson

Bayon

Molina

, et al. Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada. AIDS Care 2014; 26(12): 1555–1561.

29.

Gutierrez

Garcia

Padilla

, et al. Risk of clinically significant depression in HIV-infected patients: effect of antiretroviral drugs. HIV Med 2014; 15(4): 213–223.

30.

Ryu

Lee

Kim

, et al. Subjective memory complaints, depressive symptoms and instrumental activities of daily living in mild cognitive impairment. Int Psychogeriatr 2016; 28(3): 487–494.

31.

Santos

GMA

Locatelli

Metral

, et al. Cross-sectional and cumulative longitudinal central nervous system penetration effectiveness scores are not associated with neurocognitive impairment in a well treated aging human immunodeficiency virus-positive population in Switzerland. Open Forum Infect Dis 2019; 6(7): ofz277.

32.

Darling

Metral

, Neurocognitive Assessment in the M, Aging Cohort Study Group Swiss HIVCS, et al. Authors’ reply to A. Winston. A Cotter, M Gisslen, P W. G. Mallon and P. Cinque. HIV Med 2020; 21(7): e19–e20.